GeneDx Holdings (WGS) — Scaling AI-Driven Genomic DiagnosticsGeneDx Holdings Corp.BATS:WGSRichtv_officialCompany Overview GeneDx WGS is a genomics leader in pediatric & rare disease diagnostics, leveraging whole exome/genome sequencing and AI analytics—a direct play on the $20B+ precision medicine market. Data & Platform Edge GeneDx Infinity™: 1M+ exomes/genomes analyzed—one of the largest global repositories, enabling faster, more accurate diagnostic yield and clinical insights. FDA Breakthrough Designations: ExomeDx™ and GenomeDx™ recognized—supports reimbursement, hospital integration, and market access expansion. Execution & Financial Momentum Q3’25 revenue $116.7M (+52% YoY); sequencing volumes +33%. FY’25 guide raised to $400–$415M; 5th straight quarter of adjusted profitability—evidence of a scalable model and accelerating neonatal/pediatric adoption. Why It Wins Proprietary data flywheel (scale → accuracy → adoption). AI-first pipeline for variant interpretation and turnaround times. Structural tailwinds from newborn screening, rare disease coverage, and payer alignment. Investment Outlook Bullish above: $143–$144 Upside target: $280–$285, driven by volume growth, Breakthrough-enabled access, and operating leverage. 📌 WGS — turning genomic scale into clinical precision and durable growth.